GLP-1 Therapy Reduces Migraine Frequency by More Than Half in Obesity Patients
By
Anon84
Properly proved. Has structure, has flavour, has a point.
Summary
A study from the University of Naples found that liraglutide, a GLP-1 receptor agonist typically used for diabetes and obesity, significantly reduced migraine frequency in patients with obesity and chronic migraine. The medication cut monthly headache days by more than half, with patients reporting an average of 11 fewer headache days per month and reduced disability scores. The research suggests GLP-1 therapy may work by lowering brain fluid pressure, offering a promising new treatment approach for chronic migraine sufferers.
Key quotes
· 4 pulledResearchers at the Headache Centre of the University of Naples 'Federico II' gave the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide to 26 adults with obesity and chronic migraine
Patients reported an average of 11 fewer headache days per month, while disability scores on the MIDAS scale dropped by 68%
A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half
The study suggests GLP-1 receptor agonists may work by reducing intracranial pressure, which is often elevated in people with migraine
You might also wanna read
GLP-1 Prescriptions Rise as U.S. Obesity Rates Show Modest Decline, New Data Indicates
New data from EPIC Research shows that GLP-1 medications like Ozempic and Wegovy are having a population-wide impact on obesity rates. As pr
gizmodo.com·2d ago
GLP-1 Receptor Agonists Show Promise for Treating Extragenital Lichen Sclerosus: A Case Report
This case report describes two patients with extragenital lichen sclerosus, a chronic inflammatory skin condition, whose symptoms improved s
doi.org·5d ago